{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T17:22:58Z","timestamp":1784568178112,"version":"3.55.0"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T00:00:00Z","timestamp":1683244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of chronic myeloid leukemia (CML) but their use was associated with a range of serious cardiopulmonary toxicities including vascular adverse events, QT prolongation, heart failure, pleural effusion, and pulmonary arterial hypertension. Dedicated clinical management guidelines for TKI-induced toxicities are not available. This review aims to discuss TKI-associated cardiopulmonary toxicities and proposes a practical guide for their management.<\/jats:p>","DOI":"10.3389\/fmed.2023.1163137","type":"journal-article","created":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T06:05:13Z","timestamp":1683266713000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":27,"title":["A practical guide to managing cardiopulmonary toxicities of tyrosine kinase inhibitors in chronic myeloid leukemia"],"prefix":"10.3389","volume":"10","author":[{"given":"Rasha","family":"Kaddoura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wafer A.","family":"Dabdoob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Yassin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,5]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.3390\/ijms23052815","article-title":"Cardiotoxicity induced by protein kinase inhibitors in patients with Cancer","volume":"23","author":"Grela-Wojewoda","year":"2022","journal-title":"Int J Mol Sci"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"758010","DOI":"10.3389\/fcvm.2021.758010","article-title":"Tyrosine kinase inhibitors-induced arrhythmias: from molecular mechanisms, pharmacokinetics to therapeutic strategies","volume":"8","author":"Cheng","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"2000279","DOI":"10.1183\/13993003.00279-2020","article-title":"Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors","volume":"56","author":"Weatherald","year":"2020","journal-title":"Eur Respir J"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1714\/3766.37536","article-title":"Cardiovascular management of patients with chronic myeloid leukemia treated with BCR-ABL tyrosine kinase inhibitors: it is time for a shared management","volume":"23","author":"Maiellaro","year":"2022","journal-title":"G Ital Cardiol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"229","DOI":"10.5045\/br.2021.2021117","article-title":"A narrative review on adverse effects of dasatinib with a focus on pharmacotherapy of dasatinib-induced pulmonary toxicities","volume":"56","author":"Nekoukar","year":"2021","journal-title":"Blood Res"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"826","DOI":"10.3390\/cancers12040826","article-title":"Cardiovascular toxicity of tyrosine kinase inhibitors used in chronic myeloid leukemia: an analysis of the FDA adverse event reporting system database (FAERS)","volume":"12","author":"Cirmi","year":"2020","journal-title":"Cancers"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2147\/VHRM.S108874","article-title":"Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance","volume":"13","author":"Aghel","year":"2017","journal-title":"Vasc Health Risk Manag"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1182\/blood-2014-09-594432","article-title":"Vascular safety issues in CML patients treated with BCR\/ABL1 kinase inhibitors","volume":"125","author":"Valent","year":"2015","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13045-022-01334-z","article-title":"Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1\/2 trial [published correction appears in J Hematol Oncol. 2022 Oct 31;15(1):159]","volume":"15","author":"Jiang","year":"2022","journal-title":"J Hematol Oncol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"IJH38","DOI":"10.2217\/ijh-2021-0010","article-title":"The effect of comorbidities on the choice of tyrosine kinase inhibitors in patients with chronic myeloid leukemia","volume":"11","author":"Saydam","year":"2022","journal-title":"Int J Hematol Oncol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s40265-022-01680-9","article-title":"Olverembatinib: first approval","volume":"82","author":"Dhillon","year":"2022","journal-title":"Drugs"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s40265-021-01662-3","article-title":"Asciminib: first approval","volume":"82","author":"Deeks","year":"2022","journal-title":"Drugs"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1182\/blood-2020-139847","article-title":"Phase 1 trial of vodobatinib, a novel oral BCR-ABL1 tyrosine kinase inhibitor (TKI): activity in CML chronic phase patients failing TKI therapies including ponatinib","volume":"136","author":"Cortes","year":"2020","journal-title":"Blood"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"289","DOI":"10.3892\/ijo.2019.4801","article-title":"PF-114, a novel selective inhibitor of BCR-ABL tyrosine kinase, is a potent inducer of apoptosis in chronic myelogenous leukemia cells","volume":"55","author":"Ivanova","year":"2019","journal-title":"Int J Oncol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"801779","DOI":"10.3389\/fonc.2021.801779","article-title":"Potential approaches versus approved or developing chronic myeloid leukemia therapy","volume":"11","author":"Andretta","year":"2021","journal-title":"Front Oncol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1634\/theoncologist.2012-0466","article-title":"Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors","volume":"18","author":"Lenihan","year":"2013","journal-title":"Oncologist"},{"key":"ref17","year":""},{"key":"ref18","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1182\/asheducation-2017.1.110","article-title":"Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy","volume":"2017","author":"Barber","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"e007724","DOI":"10.1161\/JAHA.117.007724","article-title":"Incidence, diagnosis, and management of QT prolongation induced by Cancer therapies: a systematic review","volume":"6","author":"Porta-S\u00e1nchez","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1161\/CIRCULATIONAHA.111.079921","article-title":"Pulmonary arterial hypertension in patients treated by dasatinib","volume":"125","author":"Montani","year":"2012","journal-title":"Circulation"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"127","DOI":"10.6004\/jadpro.2022.13.2.4","article-title":"Cardiovascular adverse events and mitigation strategies for chronic myeloid leukemia patients receiving tyrosine kinase inhibitor therapy","volume":"13","author":"Nodzon","year":"2022","journal-title":"J Adv Pract Oncol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the international cardio-oncology society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1080\/10428194.2019.1711074","article-title":"Cardiovascular mortality among chronic myeloid leukemia patients in the pre-tyrosine kinase inhibitor (TKI) and TKI eras: a surveillance, epidemiology and end results (SEER) analysis","volume":"61","author":"Wang","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ijcard.2019.10.036","article-title":"Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors","volume":"301","author":"Caocci","year":"2020","journal-title":"Int J Cardiol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1007\/s00277-018-3375-9","article-title":"Changes in estimated glomerular filtration rate in chronic myeloid leukemia patients treated front line with available TKIs and correlation with cardiovascular events","volume":"97","author":"Molica","year":"2018","journal-title":"Ann Hematol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jaccao.2022.06.004","article-title":"Involvement of rho-associated coiled-coil containing kinase (ROCK) in BCR-ABL1 tyrosine kinase inhibitor cardiovascular toxicity","volume":"4","author":"Yu","year":"2022","journal-title":"JACC CardioOncol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.jaccao.2022.07.001","article-title":"ROCK and rolling towards predicting BCR-ABL kinase inhibitor-induced vascular toxicity","volume":"4","author":"Upshaw","year":"2022","journal-title":"JACC CardioOncol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1025392","DOI":"10.3389\/fmed.2022.1025392","article-title":"A practical guide to managing hypertension, hyperlipidemia, and hyperglycemia in patients with chronic myeloid leukemia","volume":"9","author":"Ahmed","year":"2022","journal-title":"Front Med"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"966182","DOI":"10.3389\/fcvm.2022.966182","article-title":"Cardiovascular adverse events in chronic myeloid leukemia patients treated with nilotinib or imatinib: a systematic review, meta-analysis and integrative bioinformatics analysis","volume":"9","author":"Li","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"955","DOI":"10.3324\/haematol.2018.206797","article-title":"Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German chronic myeloid leukemia-study IV","volume":"104","author":"Michel","year":"2019","journal-title":"Haematologica"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1002\/onco.13944","article-title":"Tyrosine kinase inhibitors and vascular adverse events in patients with chronic myeloid leukemia: a population-based, propensity score-matched cohort study","volume":"26","author":"Chen","year":"2021","journal-title":"Oncologist"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1038\/leu.2013.70","article-title":"Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib","volume":"27","author":"Kim","year":"2013","journal-title":"Leukemia"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1001\/jamaoncol.2015.5932","article-title":"Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response, and overall survival: a systematic review and Meta-analysis","volume":"2","author":"Douxfils","year":"2016","journal-title":"JAMA Oncol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"161","DOI":"10.7326\/M15-2306","article-title":"Cardiovascular events associated with use of tyrosine kinase inhibitors in chronic myeloid leukemia: a population-based cohort study","volume":"165","author":"Dahl\u00e9n","year":"2016","journal-title":"Ann Intern Med"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","article-title":"Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial","volume":"12","author":"Kantarjian","year":"2011","journal-title":"Lancet Oncol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1038\/leu.2012.134","article-title":"Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up","volume":"26","author":"Larson","year":"2012","journal-title":"Leukemia"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/s41375-020-01111-2","article-title":"Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis [published correction appears in leukemia. 2021 Jul;35(7):2142-2143]","volume":"35","author":"Kantarjian","year":"2021","journal-title":"Leukemia"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.3324\/haematol.2013.091272","article-title":"Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily","volume":"99","author":"Hughes","year":"2014","journal-title":"Haematologica"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.leukres.2016.07.007","article-title":"Impact of dose intensity of ponatinib on selected adverse events: multivariate analyses from a pooled population of clinical trial patients","volume":"48","author":"Dorer","year":"2016","journal-title":"Leuk Res"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1182\/blood.2021012082","article-title":"Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial","volume":"138","author":"Cortes","year":"2021","journal-title":"Blood"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.ccep.2015.03.013","article-title":"QT prolongation and oncology drug development","volume":"7","author":"Fradley","year":"2015","journal-title":"Card Electrophysiol Clin"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1161\/CIRCOUTCOMES.113.000152","article-title":"Development and validation of a risk score to predict QT interval prolongation in hospitalized patients [published correction appears in Circ Cardiovasc Qual outcomes. 2013 Nov;6(6):e57]","volume":"6","author":"Tisdale","year":"2013","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1200\/OP.20.00924","article-title":"Monitoring for chemotherapy-related Cardiotoxicity in the form of left ventricular systolic dysfunction: a review of current recommendations","volume":"17","author":"Stone","year":"2021","journal-title":"JCO Oncol Pract"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.jacc.2020.11.020","article-title":"Strain-guided management of potentially cardiotoxic cancer therapy","volume":"77","author":"Thavendiranathan","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.echo.2013.02.008","article-title":"Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity","volume":"26","author":"Negishi","year":"2013","journal-title":"J Am Soc Echocardiogr"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1182\/bloodadvances.2016003889","article-title":"The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemia","volume":"1","author":"Fox","year":"2017","journal-title":"Blood Adv"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1002\/cncr.31357","article-title":"Early results of lower dose dasatinib (50\u2009mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"124","author":"Naqvi","year":"2018","journal-title":"Cancer"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/cncr.32504","article-title":"Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"126","author":"Naqvi","year":"2020","journal-title":"Cancer"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"e902","DOI":"10.1016\/S2352-3026(21)00333-1","article-title":"Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial","volume":"8","author":"Murai","year":"2021","journal-title":"Lancet Haematol"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"K4","DOI":"10.1093\/eurheartj\/suz211","article-title":"The revised definition of pulmonary hypertension: exploring the impact on patient management","volume":"21","author":"Simonneau","year":"2019","journal-title":"Eur Heart J Suppl"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"1700217","DOI":"10.1183\/13993003.00217-2017","article-title":"Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study","volume":"50","author":"Weatherald","year":"2017","journal-title":"Eur Respir J"},{"key":"ref54","volume-title":"Lexi-Drugs","year":""}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1163137\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T11:03:29Z","timestamp":1686222209000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1163137\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,5]]},"references-count":54,"alternative-id":["10.3389\/fmed.2023.1163137"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1163137","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,5]]},"article-number":"1163137"}}